FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095679362> ?p ?o ?g. }

• W2095679362 endingPage "1570" @default.
• W2095679362 startingPage "1562" @default.
• W2095679362 abstract "¹¹¹In-DTPA–human epidermal growth factor (¹¹¹In-DTPA-hEGF [DTPA is diethylenetriaminepentaacetic acid]) is an Auger electron–emitting radiopharmaceutical that targets EGF receptor (EGFR)–positive cancer. The purpose of this study was to determine the effect of EGFR inhibition by gefitinib on the internalization, nuclear translocation, and cytotoxicity of ¹¹¹In-DTPA-hEGF in EGFR-overexpressing MDA-MB-468 human breast cancer cells. <b>Methods:</b> Western blot analysis was used to determine the optimum concentration of gefitinib to abolish EGFR activation. Internalization and nuclear translocation of fluorescein isothiocyanate–labeled hEGF were evaluated by confocal microscopy in MDA-MB-468 cells (1.3 × 10⁶ EGFRs/cell) in the presence or absence of 1 μM gefitinib. The proportion of radioactivity partitioning into the cytoplasm and nucleus of MDA-MB-468 cells after incubation with ¹¹¹In-DTPA-hEGF for 24 h at 37°C in the presence or absence of 1 μM gefitinib was measured by cell fractionation. DNA double-strand breaks caused by ¹¹¹In were quantified using the γ-H2AX assay, and radiation-absorbed doses were estimated. Clonogenic survival assays were used to measure the cytotoxicity of ¹¹¹In-DTPA-hEGF alone or in combination with gefitinib. <b>Results:</b> Gefitinib (1 μM) completely abolished EGFR phosphorylation in MDA-MB-468 cells. Internalization and nuclear translocation of fluorescein isothiocyanate–labeled EGF were not diminished in gefitinib-treated cells compared with controls. The proportion of internalized ¹¹¹In that localized in the nucleus was statistically significantly greater when ¹¹¹In-DTPA-hEGF was combined with gefitinib compared with ¹¹¹In-DTPA-hEGF alone (mean ± SD: 26.0% ± 5.5% vs. 14.6% ± 4.0%, respectively; <i>P</i> < 0.05). Induction of γ-H2AX foci was greater in MDA-MB-468 cells that were treated with ¹¹¹In-DTPA-hEGF (250 ng/mL, 1.5 MBq/mL) plus gefitinib (1 μM) compared with those treated with ¹¹¹In-DTPA-hEGF alone (mean ± SD: 35 ± 4 vs. 24 ± 5 foci per nucleus, respectively). In clonogenic assays, a significant reduction in the surviving fraction was observed when ¹¹¹In-DTPA-hEGF (5 ng/mL, 6 MBq/μg) was combined with gefitinib (1 μM) compared with ¹¹¹In-DTPA-hEGF alone (42.9% ± 5.7% vs. 22.9% ± 3.6%, respectively; <i>P</i> < 0.01). <b>Conclusion:</b> The efficacy of ¹¹¹In-DTPA-hEGF depends on internalization and nuclear uptake of the radionuclide. Nuclear uptake, DNA damage, and cytotoxicity are enhanced when ¹¹¹In-DTPA-hEGF is combined with gefitinib. These results suggest a potential therapeutic role for peptide receptor radionuclide therapy in combination with tyrosine kinase inhibitors." @default.
• W2095679362 created "2016-06-24" @default.
• W2095679362 creator A5011171192 @default.
• W2095679362 creator A5017825677 @default.
• W2095679362 creator A5023465589 @default.
• W2095679362 creator A5045329246 @default.
• W2095679362 creator A5074404084 @default.
• W2095679362 creator A5074856879 @default.
• W2095679362 creator A5081699047 @default.
• W2095679362 date "2007-08-17" @default.
• W2095679362 modified "2023-09-27" @default.
• W2095679362 title "Epidermal Growth Factor Receptor Inhibition Modulates the Nuclear Localization and Cytotoxicity of the Auger Electron Emitting Radiopharmaceutical 111In-DTPA Human Epidermal Growth Factor" @default.
• W2095679362 cites W1542246931 @default.
• W2095679362 cites W1814699096 @default.
• W2095679362 cites W1930155869 @default.
• W2095679362 cites W1964321121 @default.
• W2095679362 cites W1965549967 @default.
• W2095679362 cites W1967494335 @default.
• W2095679362 cites W1968366677 @default.
• W2095679362 cites W1992507321 @default.
• W2095679362 cites W1999281989 @default.
• W2095679362 cites W2012300394 @default.
• W2095679362 cites W2018189857 @default.
• W2095679362 cites W2022047264 @default.
• W2095679362 cites W2033725243 @default.
• W2095679362 cites W2037395954 @default.
• W2095679362 cites W2040469480 @default.
• W2095679362 cites W2064402168 @default.
• W2095679362 cites W2078889146 @default.
• W2095679362 cites W2084275823 @default.
• W2095679362 cites W2086515708 @default.
• W2095679362 cites W2098287668 @default.
• W2095679362 cites W2102872405 @default.
• W2095679362 cites W2111693820 @default.
• W2095679362 cites W2118056343 @default.
• W2095679362 cites W2118113452 @default.
• W2095679362 cites W2125251546 @default.
• W2095679362 cites W2126314379 @default.
• W2095679362 cites W2127101185 @default.
• W2095679362 cites W2150179917 @default.
• W2095679362 cites W2151772725 @default.
• W2095679362 cites W2155384808 @default.
• W2095679362 cites W2156354702 @default.
• W2095679362 cites W2163002589 @default.
• W2095679362 cites W2167398987 @default.
• W2095679362 cites W2168996492 @default.
• W2095679362 cites W2169083148 @default.
• W2095679362 cites W2188943269 @default.
• W2095679362 cites W2189849157 @default.
• W2095679362 cites W2239520447 @default.
• W2095679362 cites W2291981638 @default.
• W2095679362 cites W2283445440 @default.
• W2095679362 doi "https://doi.org/10.2967/jnumed.107.044073" @default.
• W2095679362 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17704253" @default.
• W2095679362 hasPublicationYear "2007" @default.
• W2095679362 type Work @default.
• W2095679362 sameAs 2095679362 @default.
• W2095679362 citedByCount "40" @default.
• W2095679362 countsByYear W20956793622012 @default.
• W2095679362 countsByYear W20956793622013 @default.
• W2095679362 countsByYear W20956793622014 @default.
• W2095679362 countsByYear W20956793622016 @default.
• W2095679362 countsByYear W20956793622017 @default.
• W2095679362 countsByYear W20956793622021 @default.
• W2095679362 countsByYear W20956793622022 @default.
• W2095679362 countsByYear W20956793622023 @default.
• W2095679362 crossrefType "journal-article" @default.
• W2095679362 hasAuthorship W2095679362A5011171192 @default.
• W2095679362 hasAuthorship W2095679362A5017825677 @default.
• W2095679362 hasAuthorship W2095679362A5023465589 @default.
• W2095679362 hasAuthorship W2095679362A5045329246 @default.
• W2095679362 hasAuthorship W2095679362A5074404084 @default.
• W2095679362 hasAuthorship W2095679362A5074856879 @default.
• W2095679362 hasAuthorship W2095679362A5081699047 @default.
• W2095679362 hasBestOaLocation W20956793621 @default.
• W2095679362 hasConcept C109316439 @default.
• W2095679362 hasConcept C121332964 @default.
• W2095679362 hasConcept C139770010 @default.
• W2095679362 hasConcept C1491633281 @default.
• W2095679362 hasConcept C153911025 @default.
• W2095679362 hasConcept C170493617 @default.
• W2095679362 hasConcept C185592680 @default.
• W2095679362 hasConcept C202751555 @default.
• W2095679362 hasConcept C2776362946 @default.
• W2095679362 hasConcept C2777019933 @default.
• W2095679362 hasConcept C2779438470 @default.
• W2095679362 hasConcept C2780580887 @default.
• W2095679362 hasConcept C55493867 @default.
• W2095679362 hasConcept C62520636 @default.
• W2095679362 hasConcept C86803240 @default.
• W2095679362 hasConcept C91881484 @default.
• W2095679362 hasConceptScore W2095679362C109316439 @default.
• W2095679362 hasConceptScore W2095679362C121332964 @default.
• W2095679362 hasConceptScore W2095679362C139770010 @default.
• W2095679362 hasConceptScore W2095679362C1491633281 @default.
• W2095679362 hasConceptScore W2095679362C153911025 @default.
• W2095679362 hasConceptScore W2095679362C170493617 @default.
• W2095679362 hasConceptScore W2095679362C185592680 @default.

• next